Sort
30,917 grants matching “tumor microenvironment”
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
$668,323Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting the CD73-adenosinergic pathway in head and neck cancer
$668,298Yan Cui · Augusta University · R01 · FY2024 · DE
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$668,212Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$668,154Benjamin G. Neel · New York University School Of Medicine · R01 · FY2024 · CA
Detection, Radiosensitization and Theranostic Targeting of Metastatic Breast Cancer by PTPmu
$668,144Susann M Brady-Kalnay · Case Western Reserve University · R01 · FY2025 · CA
Detection, Radiosensitization and Theranostic Targeting of Metastatic Breast Cancer by PTPmu
$668,144Susann M Brady-Kalnay · Case Western Reserve University · R01 · FY2023 · CA
Interrogating a white matter degeneration-specific astrocyte reactivity state and its role in governing repair-associated microglia specification and function.
$668,128Joshua Evan Burda · Cedars-Sinai Medical Center · R01 · FY2024 · NS
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
$668,053Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy
$668,018Harriet M Kluger · Yale University · R01 · FY2023 · CA
Direct targeting of HIF1a-driven transcription in TNBC with engineered STRs
$667,792Raymond E Moellering · University Of Chicago · R01 · FY2025 · CA
Direct targeting of HIF1a-driven transcription in TNBC with engineered STRs
$667,792Raymond E Moellering · University Of Chicago · R01 · FY2024 · CA
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
$667,761Meenakshi G Hegde · Baylor College Of Medicine · R01 · FY2023 · CA
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
$667,694Alain Charest · Beth Israel Deaconess Medical Center · R01 · FY2018 · CA
Metabolic regulation of immunosuppressive myeloid cells in the tumor microenvironment of pancreatic cancer.
$667,601Yaqing Zhang · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV
$667,553Seth M Pollack · Northwestern University At Chicago · R01 · FY2025 · CA
Angiogenesis and Tumor Growth
$667,388Giovanna Tosato · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
The Role of TIMPs in Cell Growth, Tumor Progression and Metastasis
$667,359William Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
$667,174Amir Horowitz · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Development and validation of an autologous mouse model for the study of immune interactions with glioblastoma
$667,171Zev Ari Binder · University Of Pennsylvania · R37 · FY2025 · CA
Identifying and disabling new pathways for macromolecular recycling in pancreatic cancer
$667,118Rushika Miriam Perera · University Of California, San Francisco · R01 · FY2025 · CA
A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers
$666,962Nancy Y Lee · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer
$666,956Benjamin G. Neel · New York University School Of Medicine · R01 · FY2024 · CA
Mapping Immune Contexture and Crosstalk with Tumor Cells At GBM Margin
$666,772Hongyan Jenny Zou · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · NS
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases
$666,767Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2023 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases
$666,767Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2022 · CA